Angiotensin II in the evolution of experimental heart failure. 1996

A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minn. 55905, USA. luchner.andreas@mayo.edu

Although angiotensin II (Ang II) has been implicated in the pathophysiology of congestive heart failure, its temporal and regional changes during the development and progression of the disease are poorly defined. Our objective was to assess circulating, renal, cardiac, and vascular Ang II in a canine model of rapid ventricular pacing-induced heart failure that evolves from early left ventricular dysfunction to overt congestive heart failure. Ang II was measured by radioimmunoassay with low cross-reactivity to other angiotensins. Control, early left ventricular dysfunction, and overt congestive heart failure dogs were studied. Early left ventricular dysfunction was characterized by impaired cardiac function, cardiac enlargement, preserved renal perfusion pressure, maintained urinary sodium excretion, and normal plasma renin activity. Overt congestive heart failure was characterized by further impaired cardiac function and cardiac enlargement, reduced renal perfusion pressure, urinary sodium retention, and increased plasma renin activity and plasma Ang II. In early left ventricular dysfunction dogs, renal cortical, renal medullary, ventricular, and aortic Ang II were unchanged, and atrial Ang II was decreased. In overt congestive heart failure dogs, Ang II was increased in the kidney and heart compared with normal dogs and in all tissues compared with early left ventricular dysfunction dogs. The greatest increase in tissue Ang II occurred in the renal medulla. We conclude that early increases in local renal, myocardial, and vascular Ang II do not occur in this model of early left ventricular dysfunction and may even be suppressed. In contrast, increased myocardial and particularly renal Ang II in association with increased circulating Ang II are hallmarks of overt experimental congestive heart failure. These studies provide new insights into the temporal and regional alterations in Ang II during the progression of experimental congestive heart failure.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
December 2005, Journal of clinical hypertension (Greenwich, Conn.),
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
April 2007, Nihon rinsho. Japanese journal of clinical medicine,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
January 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
June 1999, Journal of cardiac failure,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
May 1978, Archives internationales de pharmacodynamie et de therapie,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
February 2003, Pharmacotherapy,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
November 2003, Cardiovascular research,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
September 1999, Cardiovascular research,
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
July 1998, Heart (British Cardiac Society),
A Luchner, and T L Stevens, and D D Borgeson, and M M Redfield, and J E Bailey, and S M Sandberg, and D M Heublein, and J C Burnett
January 2006, Cardiology in review,
Copied contents to your clipboard!